Literature DB >> 21316599

PARP inhibitors in cancer therapy: promise, progress, and puzzles.

Leif W Ellisen1.   

Abstract

A recent article in the New England Journal of Medicine by O'Shaughnessy et al. provides evidence that a treatment strategy aimed at inducing DNA damage with chemotherapy while simultaneously disabling repair using a PARP inhibitor might offer hope for patients with a treatment-refractory form of breast cancer.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Year:  2011        PMID： 21316599      PMCID： PMC3070420          DOI： 10.1016/j.ccr.2011.01.047

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  9 in total

Review 1.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

Review 2.  Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics.

Authors:  Jin-xue He; Chun-hao Yang; Ze-hong Miao
Journal:  Acta Pharmacol Sin       Date:  2010-08-02       Impact factor: 6.150

3.  Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

Authors:  Joyce O'Shaughnessy; Cynthia Osborne; John E Pippen; Mark Yoffe; Debra Patt; Christine Rocha; Ingrid Chou Koo; Barry M Sherman; Charles Bradley
Journal:  N Engl J Med       Date:  2011-01-05       Impact factor: 91.245

4.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

Authors:  Andrew Tutt; Mark Robson; Judy E Garber; Susan M Domchek; M William Audeh; Jeffrey N Weitzel; Michael Friedlander; Banu Arun; Niklas Loman; Rita K Schmutzler; Andrew Wardley; Gillian Mitchell; Helena Earl; Mark Wickens; James Carmichael
Journal:  Lancet       Date:  2010-07-06       Impact factor: 79.321

Review 5.  The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets.

Authors:  Raga Krishnakumar; W Lee Kraus
Journal:  Mol Cell       Date:  2010-07-09       Impact factor: 17.970

6.  miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors.

Authors:  Patryk Moskwa; Francesca M Buffa; Yunfeng Pan; Rohit Panchakshari; Ponnari Gottipati; Ruth J Muschel; John Beech; Ritu Kulshrestha; Kotb Abdelmohsen; David M Weinstock; Myriam Gorospe; Adrian L Harris; Thomas Helleday; Dipanjan Chowdhury
Journal:  Mol Cell       Date:  2010-12-30       Impact factor: 17.970

7.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.

Authors:  Helen E Bryant; Niklas Schultz; Huw D Thomas; Kayan M Parker; Dan Flower; Elena Lopez; Suzanne Kyle; Mark Meuth; Nicola J Curtin; Thomas Helleday
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

8.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors:  Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245

9.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Authors:  Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504
  9 in total
  23 in total

1.  BAL1 and its partner E3 ligase, BBAP, link Poly(ADP-ribose) activation, ubiquitylation, and double-strand DNA repair independent of ATM, MDC1, and RNF8.

Authors:  Qingsheng Yan; Rong Xu; Liya Zhu; Xin Cheng; Zhe Wang; John Manis; Margaret A Shipp
Journal:  Mol Cell Biol       Date:  2012-12-10       Impact factor: 4.272

2.  Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.

Authors:  Likun Li; Wenjun Chang; Guang Yang; Chengzhen Ren; Sanghee Park; Theodoros Karantanos; Styliani Karanika; Jianxiang Wang; Jianhua Yin; Parantu K Shah; Hirayama Takahiro; Masato Dobashi; Wenling Zhang; Eleni Efstathiou; Sankar N Maity; Ana M Aparicio; Elsa M Li Ning Tapia; Patricia Troncoso; Bradley Broom; Lianchun Xiao; Hyun-Sung Lee; Ju-Seog Lee; Paul G Corn; Nora Navone; Timothy C Thompson
Journal:  Sci Signal       Date:  2014-05-20       Impact factor: 8.192

3.  Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.

Authors:  J Chad Brenner; Bushra Ateeq; Yong Li; Anastasia K Yocum; Qi Cao; Irfan A Asangani; Sonam Patel; Xiaoju Wang; Hallie Liang; Jindan Yu; Nallasivam Palanisamy; Javed Siddiqui; Wei Yan; Xuhong Cao; Rohit Mehra; Aaron Sabolch; Venkatesha Basrur; Robert J Lonigro; Jun Yang; Scott A Tomlins; Christopher A Maher; Kojo S J Elenitoba-Johnson; Maha Hussain; Nora M Navone; Kenneth J Pienta; Sooryanarayana Varambally; Felix Y Feng; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2011-05-17       Impact factor: 31.743

4.  Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts.

Authors:  Padmini S Kedar; Donna F Stefanick; Julie K Horton; Samuel H Wilson
Journal:  Mol Cancer Res       Date:  2012-01-13       Impact factor: 5.852

5.  Uterine serous carcinoma: increased familial risk for lynch-associated malignancies.

Authors:  Summer B Dewdney; Nora T Kizer; Abegail A Andaya; Sheri A Babb; Jingqin Luo; David G Mutch; Amy P Schmidt; Louise A Brinton; Russell R Broaddus; Nilsa C Ramirez; Phyllis C Huettner; Donald Scott McMeekin; Kathleen Darcy; Shamshad Ali; Patricia L Judson; Robert S Mannel; Shashikant B Lele; David M O'Malley; Paul J Goodfellow
Journal:  Cancer Prev Res (Phila)       Date:  2012-01-13

6.  Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.

Authors:  Likun Li; Styliani Karanika; Guang Yang; Jiangxiang Wang; Sanghee Park; Bradley M Broom; Ganiraju C Manyam; Wenhui Wu; Yong Luo; Spyridon Basourakos; Jian H Song; Gary E Gallick; Theodoros Karantanos; Dimitrios Korentzelos; Abul Kalam Azad; Jeri Kim; Paul G Corn; Ana M Aparicio; Christopher J Logothetis; Patricia Troncoso; Timothy Heffernan; Carlo Toniatti; Hyun-Sung Lee; Ju-Seog Lee; Xuemei Zuo; Wenjun Chang; Jianhua Yin; Timothy C Thompson
Journal:  Sci Signal       Date:  2017-05-23       Impact factor: 8.192

7.  Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

Authors:  Daniel Morgensztern; Meghan J Campo; Suzanne E Dahlberg; Robert C Doebele; Edward Garon; David E Gerber; Sarah B Goldberg; Peter S Hammerman; Rebecca S Heist; Thomas Hensing; Leora Horn; Suresh S Ramalingam; Charles M Rudin; Ravi Salgia; Lecia V Sequist; Alice T Shaw; George R Simon; Neeta Somaiah; David R Spigel; John Wrangle; David Johnson; Roy S Herbst; Paul Bunn; Ramaswamy Govindan
Journal:  J Thorac Oncol       Date:  2015-01       Impact factor: 15.609

8.  ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.

Authors:  Jianfeng Shen; Yang Peng; Leizhen Wei; Wei Zhang; Lin Yang; Li Lan; Prabodh Kapoor; Zhenlin Ju; Qianxing Mo; Ie-Ming Shih; Ivan P Uray; Xiangwei Wu; Powel H Brown; Xuetong Shen; Gordon B Mills; Guang Peng
Journal:  Cancer Discov       Date:  2015-06-11       Impact factor: 39.397

9.  HUS1 regulates in vivo responses to genotoxic chemotherapies.

Authors:  G Balmus; P X Lim; A Oswald; K R Hume; A Cassano; J Pierre; A Hill; W Huang; A August; T Stokol; T Southard; R S Weiss
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

Review 10.  NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential.

Authors:  Na Xie; Lu Zhang; Wei Gao; Canhua Huang; Peter Ernst Huber; Xiaobo Zhou; Changlong Li; Guobo Shen; Bingwen Zou
Journal:  Signal Transduct Target Ther       Date:  2020-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.